Interim Management Statement

News Release

14 March 2011

Consort Medical plc

Interim Management Statement

Consort Medical plc (LSE: CSRT), today issues its interim management statement for the period from 1 November 2010 to date.

Bespak has continued to trade strongly, with robust valve volumes and an encouraging order book. The development pipeline continues to progress and the Board was pleased to announce in February its investment in Atlas Genetics as part of Consort's growth strategy at the same time that Bespak was awarded a development contract with Atlas.

As previously indicated, King Systems has experienced lower trading volumes in recent months, with end user markets remaining sluggish. The transformation programme remains on track and the initial market response to the upcoming launch of the King Vision video laryngoscope has been encouraging.

There has been no significant change in the Group's financial position since the publication of the Group's interim results for the six months ended 31 October 2010 in December 2010. The Group remains strongly cash generative.

The Board remains confident about the outlook for the full year.

For enquiries, please contact:

Consort Medical plc is a leader in medical devices for inhaled drug delivery, self-injection and anaesthesia. The Group develops drug delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings in hospitals.

Consort Medical develops and manufactures metered dose inhaler valves, actuators, compliance aids, dry powder devices autoinjectors, disposable facemasks, breathing circuits and laryngeal tubes. The Group has facilities in King's Lynn, Sheffield, Nelson and Hemel Hempstead in the UK, and Indianapolis, Indiana and Kent, Ohio in the US. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT).